Compositions and methods for targeted delivery to retinal cells

Porous nanoparticles coated with ionic liquids and functionalized with antibodies address the challenge of targeting retinal cells, offering improved drug delivery and reduced cytotoxicity for effective treatment of retinal diseases.

WO2026111656A1PCT designated stage Publication Date: 2026-05-28CASBIO (S) PTE LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
CASBIO (S) PTE LTD
Filing Date
2025-11-21
Publication Date
2026-05-28

AI Technical Summary

Technical Problem

Existing drug delivery systems struggle to effectively target retinal cells due to the blood-retinal barrier and densely packed cellular structures, leading to limited drug permeation and potential unintended effects on ocular cells, especially for retinal ganglion cells, which have limited self-repair capacity and result in irreversible vision loss.

Method used

Development of porous nanoparticles coated with an ionic liquid and functionalized with targeting moieties, such as antibodies, to enhance cellular uptake and selective delivery to retinal cells, particularly retinal ganglion cells.

Benefits of technology

The nanoparticles provide improved drug delivery to retinal cells with reduced cytotoxicity, increased uptake, and selective binding, enabling effective treatment of retinal diseases and potential gene therapy applications with enhanced safety and reduced immune response.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure IMGF000004_0001
    Figure IMGF000004_0001
  • Figure IMGF000004_0002
    Figure IMGF000004_0002
  • Figure IMGF000024_0001
    Figure IMGF000024_0001
Patent Text Reader

Abstract

The present disclosure provides nanoparticle compositions for targeted drug delivery to retinal cells. The nanoparticles comprise a porous core that is at least partially coated with an ionic liquid. Targeting moieties conjugated to the core direct the nanoparticles to retinal cells. In one embodiment, the nanoparticle comprises polymeric bridged periodic mesoporous organosilica (PMO) - amino acid ionic liquid, linked to antibodies specific to retinal ganglion cells (RGCs). Also provided are methods of preparing the nanoparticles and methods of using the nanoparticles for treatment of retinal diseases.
Need to check novelty before this filing date? Find Prior Art